Bibliography
- Cernaro V, Trifirò G, Lorenzano G, et al. New therapeutic strategies under development to halt the progression of renal failure. Expert Opin Investig Drugs 2014;23(5):693-709
- Robin X, Creixell P, Radetskaya O, et al. Personalized network-based treatments in oncology. Clin Pharmacol Ther 2013;94:646-50
- Schmitter D, Cotter G, Voors AA. Clinical use of novel biomarkers in heart failure: towards personalized medicine. Heart Fail Rev 2014;19(3):369-81
- Pesce F, Pathan S, Schena FP. From omics to personalized medicine in nephrology: integration is the key. Nephrol Dial Transplant 2013;28:24-8
- Lampreabe I, Gainza de los Rios FJ, Arrieta Gutiérrez A, et al. Toward personalized medicine in renal transplantation. Transplant Proc 2010;42:2864-7
- Pharmacogenomics a knowledge database. Available from: www.pharmgkb.org
- Pérez-Oller L, Torra R, Badenas C, et al. Influence of the ACE gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease. Am J Kidney Dis 1999;34:273-8
- Wang AY, Chan JC, Wang M, et al. Cardiac hypertrophy and remodeling in relation to ACE and angiotensinogen genes genotypes in Chinese dialysis patients. Kidney Int 2003;63:1899-907
- Takada K, Arefayene M, Desta Z, et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 2004;50:2202-10
- De Jonge H, Kuypers DR. Pharmacogenetics in solid organ transplantation: current status and future directions. Transplant Rev 2008;22:6-20
- Kuypers DR, Naesens M, Vermeire S, et al. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 2005;78:351-61
- Albert D, Dunham J, Khan S, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 2008;67:1724-31
- Granata S, Zaza G, Simone S, et al. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics 2009;10:388
- Zaza G, Pontrelli P, Pertosa G, et al. Dialysis-related systemic microinflammation is associated with specific genomic patterns. Nephrol Dial Transplant 2008;23:1673-81
- Kottgen A, Kao WH, Hwang SJ, et al. Genome-wide association study for renal traits in the Framingham Heart and Atherosclerosis Risk in Communities Studies. BMC Med Genet 2008;9:49
- Urbschat A, Obermüller N, Haferkamp A. Biomarkers of kidney injury. Biomarkers 2011;16(Supp 1):S22-30
- Bruno S, Camussi G. Role of mesenchymal stem cell-derived microvesicles in tissue repair. Pediatr Nephrol 2013;28:2249-54
- Sallustio F, Costantino V, Cox SN, et al. Human renal stem/progenitor cells repair tubular epithelial cell injury through TLR2-driven inhibin-A and microvescicle-shuttled decorin. Kidney Int 2013;83:392-403
- Cox SN, Sallustio F, Serino G, et al. Altered modulation of WNT-beta-catenin and PI3K/Akt pathways in IgA nephropathy. Kidney Int 2010;78:396-407
- Cox SN, Sallustio F, Serino G, et al. Activated innate immunity and the involvement of CX3CR1-fractalkine in promoting hematuria in patients with IgA nephropathy. Kidney Int 2012;82:548-60
- Dell’Oglio MP, Zaza G, Rossini M, et al. The anti-fibrotic effect of mycophenolic acid-induced neutral endopeptidase. J Am Soc Nephrol 2010;21:2157-68
- Argilés A, Siwy J, Duranton F, et al. CKD273, a new proteomics classifier assessing CKD and its prognosis. PLoS One 2013;8:e62837
- Goek ON, Prehn C, Sekula P, et al. Metabolites associate with kidney function decline and incident chronic kidney disease in the general population. Nephrol Dial Transplant 2013;28:2131-8
- Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007;6:287-93